Let's Talk Quality

Let's Talk Quality

Download on the App Store

All Let's Talk Quality episodes

  • Joe Franchetti, on his vision for the Society of Quality Assurance (SQA)

    Joe Franchetti, President of the Society of Quality Assurance (SQA), shares his vision for the SQA and the wider quality assurance industry, emphasizing the importance of collaboration and expanding relationships with international quality colleagues and regulators. Joe highlights the need to attract and educate younger professionals about the field of quality assurance. He discusses the role of technology, including AI and blockchain, the challenges and opportunities they present, as well as offering advice for future quality assurance professionals.

    • 01:25 - Election as President of SQA
    • 05:09 - Vision for SQA and the Quality Assurance Industry
    • 07:27 - Promoting Quality Assurance as a Career
    • 10:09 - Challenges in Attracting Young Professionals to Quality Assurance
    • 13:39 - The Role of Technology in Quality Assurance
    • 27:26 - Advice for Future Quality Assurance Professionals
    • 29:04 - Joe's Inspiration and Motivation
    • 31:02 - Information about SQA and its Benefits

    It was a privilege to be joined by Joe and hear him discuss his vision for the SQA, the wider industry, the role that technology will play, and what benefits the SQA can offer to future and existing members.

    Thanks for listening, I hope you enjoy the show!

    39 min
  • Laurie Adami on how CAR-T cell therapy saved her life

    This is very special episode. I was joined by Laurie Adami, a financial services exec who was forced to give up her career after a cancer diagnosis in 2006.

    After a 12 year battle fighting follicular non-Hodgkin lymphoma, and six lines of therapy, Laurie received a call from her oncologist, informing her about a new therapy called CAR-T, that was being developed by Kite Pharma.

    They were opening a clinical trial at UCLA with five patients. Laurie was to be patient number one. One month after her CAR-T treatment, Laurie was in complete remission.

    Laurie is now focused on patient advocacy, volunteering and fundraising for cancer research, especially CAR-T immunotherapy.

    I wanted to speak with Laurie, to talk about her fight against follicular non-Hodgkin lymphoma, how she learnt about a new game-changing therapy called CAR-T, and some key issues around access to patients, safety concerns raised by the FDA, bridging the gap between industry and patients, and what she is doing now to raise awareness of the benefits and potential of CAR-T. We discuss the following:

    • [2:40] Laurie's Diagnosis, Initial Treatment and Challenges
    • [5:00] 12 Year Cycle of Six Lines of Therapy and Relapse
    • [10:55] Hearing the Story of Emily Whitehead and CAR-T in 2012
    • [14:22] Starting Sixth Line of Therapy in 2016
    • [14:57] Receiving a call about a CAR-T Trial in Spring, 2018
    • [18:55] Going Through CAR-T Cell Therapy
    • [21:32] Complete Remission
    • [24:18] Becoming a Patient Advocate Volunteer
    • [26:41] Patient Access and Challenges
    • [35:41] Laurie's Response to the FDA Safety Advisory on CAR-T
    • [41:30] Bridging the Gap Between Industry and Patients
    • [46:16] The Potential and Future of CAR-T Therapy
    • [51:34] Living Life to the Full
    • [58:41] Meeting the People that Saved Her Life

    I really hope people enjoy listening to Laurie's story and that it gives hope to anyone affected by Cancer, and raises awareness of the potential for CAR-T Cell Therapy to save more lives.

    There are a number of challenges that Laurie is on a mission to tackle, and I would urge people to listen to this episode to learn more about how we can bridge the gap between the industry and patients, and get safter, faster and more affordable access of these therapies to more patients like Laurie.

    Thank you Laurie for sharing your story with us!

    1 hr 3 min
  • Kimberly Wallbank on how to transition into the world of contracting

    In this conversation, Kimberly Wallbank, a quality systems consultant in the pharma & biotech industry, shares her insights and experiences in the world of contracting. She discusses the changes in the contracting market, the types of projects she takes on, and the shift towards remote and on-site work. Kimberly also provides advice on building a network and finding contracts, including the importance of volunteering and referrals. She emphasizes the need for flexibility, problem-solving skills, and a strong support system when starting out in contracting.

    • Kimberly's Background and Consulting Work
    • Reasons for Getting into Contracting
    • Changes in the Contracting World
    • Types of Projects and Team Sizes
    • Shifts in Remote and On-Site Work
    • Building a Network and Finding Contracts
    • Volunteering and Referrals
    • Dealing with Slowdowns in the Market
    • Skills Needed for Consulting
    • Motivation and Enjoyment as a Consultant
    • Advice for Starting Out in Contracting

    This is a conversation which is worth listening for anyone considering become a contractor. The contracting market has seen changes, with more consultants entering the market and building a network and proactively finding contracts can be a challenge without the right support systems. Kimberly shares how flexibility, problem-solving skills, and the ability to adapt to different business models are important for success as a consultant.

    Hope you enjoy the show!

    32 min
  • Stan Russell on how to create a value-adding quality function.

    This week I speak with Stan Russell, who explains how quality leaders can create a function that adds true value to an organisation.

    Stan provides practical advice for leaders to change perceptions and measure the strength of a quality culture. He also shares his leadership style and the importance of storytelling and analogies in articulating quality to the organisation, which can result in a function that is seen as truly valuable. We discuss the following:

    • What is a 'Quality Culture' and why is it important?
    • Evolution of the perception of quality
    • How to measure the strength of a quality culture
    • Practical steps for changing perceptions
    • Utilizing management review to enhance your value
    • How to facilitate team development
    • Stan's leadership style and analogies he has used to communicate
    • Advice for future quality leaders
    • The 'one' soft-skill that Stan would advise leaders to develop

    This is a fascinating insight into how quality leaders can ensure they are creating a function that puts people and the patient first, whilst enhancing the value and perception of the quality function within their organisation.

    Stan is a true leader with an exceptional track record of quality leadership in enterprise and start-up organisations. A huge thank you for coming on the show.

    39 min
  • Vaishali Shukla on Quality Oversight in Global Pharmaceutical Operations

    This week I was joined by Vaishali Shukla, VP of Global Quality Manufacturing at Kite Pharma.

    "Act locally but think globally”. This is the mindset that Vaishali has helped instil in her role to help harmonize processes, engage the global network, and create a 'one team' quality approach.

    Vaishali talks us through her journey in quality and some of the challenges of leading a global quality operation of 500+ people, and the key aspects which have helped her to get to where she is now. We discuss the below points:

    • The challenges of managing a global quality operation.
    • Navigating the pandemic and transitioning into a remote world.
    • Managing people in time-zones across the US, Europe, and Asia.
    • Staying relevant with guidelines across different jurisdictions.
    • Balancing compliance and innovation in the cell therapy industry.
    • How to manage M&A and the complex transition that takes place.
    • The evolution of guidelines and technology over the past two decades.
    • How to stay relevant in a constantly evolving landscape.
    • The skills Vaishali has developed to progress to where she is now.
    • Vaishali's outlook on leadership, and within the ATMP space.

    Whether you want to work in a global operation or small biotech, this is a must listen for any current or aspiring quality leader. So many great insights into the mindset of a highly successful quality leader and some key traits to help accelerate your own leadership career.

    I hope you enjoy the show!

    28 min
  • Greg Furrow on the risks of trusting 'expert opinions'.

    As a biotech professional, how do you know that the questions you ask 'experts' are accurate?

    Is the answer based on explicit regulations? Or is it based on personal opinion, which has been formed by historical organisational practise?

    In this episode, Greg Furrow, Chief Quality Officer of Mustang Bio, discusses his mission to raise awareness around the importance of industry 'experts' providing accurate and evidence-based information, rather than relying solely on personal experience or company practice.

    As a recognised 'expert' himself, Greg talks about organisations and individuals giving disclaimers about their opinions. He encourages both experts and learners to prioritize understanding compliance and to seek the facts rather than blindly trusting opinions. We discuss the following:

    • The Importance of Understanding Compliance
    • The Risk of Mistakes and Misinformation
    • Clear Regulations in the Biotech Industry
    • Answering Compliance Questions in ATMP's
    • The Goal of Understanding Compliance
    • Obligations of Leaders in Answering Questions
    • Advice for Future Quality Assurance Professionals
    • What Inspires Greg in his Career.

    Huge thanks to Greg for sharing his views and raising awareness around this important matter. Greg is on a mission to move away from giving subjective personal opinions based on organisational practises - towards a compliance framework anchored in explicit regulations and guidance documents.

    Enjoy the show!

    34 min
  • Jason Treese on leading the commercialisation of BMS' first approved cell therapies

    This is a story about the journey of commercialization for BMS' first cell therapies approved for the treatment of blood cancer.

    Jason 'Jake' Treese, played a critical role in the development, approval and commercialization of Abecma and Breyanzi; two cell therapies which have now treated 4,700 patients in clinical and commercial settings - patients that are often on their last line of treatment, and last hope of a successful treatment.

    We discuss leading the quality function in CAR-T cell therapy, the challenges faced in gaining approval for these therapies, the background of CAR-T cell therapy, the importance of building a strong team, the setbacks encountered during the approval process, and the motivation and inspiration behind the work.

    • Understanding CAR-T Cell Therapy
    • Leading the Quality Function in CAR-T Cell Therapy
    • Building the Team and Planning for Success
    • Challenges and Setbacks in the Approval Process
    • Maintaining Motivation and Mission
    • The Approval and Reflections
    • Advice for Quality Leaders in Cell Therapy
    • Considerations for the Industry
    • Reflections on the Impact of Cell Therapy

    It's an incredible, emotional, and highly insightful story. For anyone that is leading an organisation through clinical development, particularly within cell therapy, this is a must listen!

    46 min
  • Emily English on scaling for success in RNA cell therapy.

    This week on the podcast I speak with Emily English, VP of Quality at Cartesian Therapeutics.

    Cartesian is a clinical-stage biopharmaceutical company developing RNA cell therapies designed to benefit the wide range of patients with cancer, autoimmune diseases, and respiratory diseases. We discussed RNA cell therapy and how Cartesian are bringing forward their mission of developing safer cell therapies for patients with autoimmune diseases. We talk about the following in detail:

    • The work Cartesian are doing in RNA cell therapy and why it is exciting for patients.
    • How early data suggests that Cartesian's lead programme can provide durable therapeutic benefit to patients with autoimmune diseases.
    • Why Cartesian brought manufacturing in-house, the implications and the benefits of internal manufacturing.
    • The transition in thinking and managing for risk and potential downtimes in the future versus planning for success.
    • The challenges of bringing autologous cell therapies to patients at scale.
    • Creating scalable processes for commercialisation, ensuring sustainability, and streamlining quality processes.
    • At which stage in clinical development should organisations be thinking about creating scalable processes.
    • How Cartesian are changing the way traditional cell therapies are developed and the implications of these changes.
    • Emily’s values, her outlook on leadership, and what inspires her.

    It was a pleasure to speak with Emily. It’s hugely exciting to see the incredibly innovative work that her and the team at Cartesian are doing to help patients suffering from autoimmune diseases. I’m looking forward to seeing the progress that Emily and her team make in bringing these therapies closer to the patients as they scale in a commercial setting.

    We will definitely have another conversation in 12 months time to see how things are progressing at Cartesian!

    I hope you enjoy the show!

    31 min
  • Brian Furmanski on how to achieve a culture of data integrity excellence.

    The volume of data integrity violations cited in FDA warning letters has risen alarmingly over the last decade.

    Several examples of poor data integrity practises have demonstrated the consequences it can have on a biotech's future, particularly when is occurs at an early stage of development.

    In episode 11 of Let's Talk Quality, I was joined by Brian Furmanski, Chief Regulatory Officer for Kriya Therapeutics.

    Brian has a large remit, covering regulatory, quality and clinical, and is passionate about all things data. He speaks about his background with the FDA, his journey to Kriya, and how he is implementing a culture of data integrity in his current role. We discuss the following:

    • The importance of data integrity in pharma and biotech.
    • What does good data integrity look like?
    • How Brian drives a culture of data integrity in his current role.
    • Data integrity gone wrong - real life examples.
    • The consequences of poor data integrity practises.
    • When biotech's should be thinking about developing more robust quality systems.
    • How to start building better data integrity practises into your business.
    • The challenges of overseeing multiple functions in a start-up biotech.

    Huge thanks to Brian for joining us on the show and sharing some best practises for implementing great data integrity practises. For a biotech leader, especially if you're in preclinical studies, ensuring you are implementing and embedding a culture that drives data integrity excellence is paramount to your future success.

    I hope you enjoy the show!

    31 min
  • Jacob Patterson on the skills you need to develop now, to be a quality leader of the future.

    This week I spoke with Jacob Patterson, VP quality for a clinical stage biotech in Rhode Island.

    Jacob, by his own admission, has had to continuously adapt, learn and be flexible in his approach to quality leadership. We had a great conversation about what skills the quality industry will demand in the next 10-20 years. We spoke about what Jacob thinks quality professionals should be doing now, from both a technical skills and a leadership perspective to help grow their career, develop succession, and become a great quality assurance leader in the future. We covered the below in detail:

    • Working in a smaller biotech compared to larger organizations
    • What makes a high performing quality function today?
    • How times have changed and why quality isn't known as the police any more
    • How speed, agility and data analysis are the skills quality professionals need to be learning now
    • Data integrity and analysis, and it's significance
    • How the industry can develop more quality leaders
    • Managing people and how to deal with difficult employees
    • Defining the ROI of quality and getting quality a better seat at the table
    • What to look for in your people when building a team

    Thank you to Jacob for giving us his insights into the world of quality assurance and it's future. Jacob is honest about his assessment of the current landscape of quality assurance and what he believes, the skills that QA professionals should be working on now, to build a successful career for the future.

    Hope you enjoy the show!

    38 min